局限型前列腺癌组织基因组检测的社会人口学因素关联
该回顾性研究纳入2012至2022年诊断为局限型前列腺癌的2103例患者,评估社会人口学因素与基因组分类检测使用的关系。结果显示40.1%患者接受了检测,最不贫困地区检测比例高于最贫困地区,调整后高龄、西班牙裔及居住于更贫困地区与检测几率降低相关。
要点
- 局限型前列腺癌患者中基因组分类检测使用率为40.1%。
- 最不贫困地区检测比例40.9%,高于最贫困地区的34.6%(P<.001)。
- 调整临床病理因素后,高龄、西班牙裔和更贫困地区与检测几率降低相关。
核心结论
- 居住在社会劣势更高地区及西班牙裔患者使用基因组检测的比例更低,提示 discretionary 风险评估工具存在人口学差异。
研究设计与样本
- 回顾性研究,纳入2012-2022年诊断为局限型前列腺癌并接受基因组检测的患者2103例,收集临床、区域贫困指数(ADI)和保险信息。
主要发现
- 2103例 eligible 患者中40.1%接受基因组检测,其中97.5%有ADI信息。
- 最不贫困地区检测比例40.9%,最贫困地区34.6%(P<.001)。
- 调整临床和病理因素后,活检时年龄、西班牙裔 ethnicity 和居住于更贫困地区与接受GC检测的 odds 降低相关。
- 在接受检测的患者中,ADI与GC风险无显著关联(所有P值>.05)。
临床怎么用
- 临床决策中使用基因组分类检测时,应关注患者居住地区贫困程度和族裔背景可能带来的检测可及性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association of patient and area-level sociodemographic factors associated with the use of genomic classifiers (GC) testing for localized prostate cancer (PCa). Although GC can improve stratification of PCa risk and facilitate personalization of treatment decision making, the factors influencing a patient's use of GCs remains poorly characterized. METHODS: We conducted a retrospective study to identify patients who were diagnosed with localized PCa from 2012-2022 and received genomic testing. We compiled clinical, Area Deprivation Index (ADI), and health insurance information. The primary study outcome was receipt of the GC assay from biopsy. Logistic regression analyses were used to evaluate the association between ADI and receipt of a GC test. RESULTS: Among 2103 eligible patients, 40.1% underwent genomic testing, and of those, 97.5% had available ADI information. A higher proportion of patients in the least deprived areas received genomic testing (40.9%) compared to those in the most deprived areas (34.6%) (P < .001). When adjusting for clinical and pathologic factors, age at time of biopsy, Hispanic ethnicity, and residence in a more deprived area were associated with lower odds of receiving a GC test. Among tested patients, ADI was not significantly associated with GC risk (all P-values >.05). CONCLUSION: Use of genomic testing was lower in patients living in areas with higher levels of social disadvantage, as well as patients of Hispanic ethnicity. These findings highlight demographic differences in the use of discretionary risk assessment tools for PCa.
引用
- Diaz GM, Sivanesan N, Strachan S, et al. Sociodemographic Factors Associated With Tissue-based Genomic Testing for Prostate Cancer. Urology. 2025. PMID: 41412501. doi:10.1016/j.urology.2025.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。